ArticleContemporary clinical trials communications2020
Leveraging analytics to assure quality during the Covid-19 pandemic - The COVACTA clinical study example.
Article in Contemporary clinical trials communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Statistical Modeling for Quality Risk Assessment of Clinical Trials: Follow-Up at the Era of Remote Auditing.Therapeutic innovation & regulatory science · 2022Article
- COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment - A narrative review.Best practice & research. Clinical anaesthesiology · 2021Review
- Clinical Quality Considerations when Using Next-Generation Sequencing (NGS) in Clinical Drug Development.Therapeutic innovation & regulatory science · 2021Review
- Cross-company collaboration to leverage analytics for clinical quality and accelerate drug development: The IMPALA industry group.CPT: pharmacometrics & systems pharmacology · 2021Article
- Clinical Quality in Cancer Research: Strategy to Assess Data Integrity of Germline Variants Inferred from Tumor-Only Testing Sequencing Data.Pharmaceutical medicine · 2021Article
- Letter to the Editor: New Approaches to Regulatory Innovation Emerging During the Crucible of COVID-19.Therapeutic innovation & regulatory science · 2021Article
- When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It.Journal of clinical medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The world has seen a shift in the ways of working during the Covid-19 pandemic. Routine activities performed at the clinical investigator sites (e.g. on-site audits) that are a part of Quality Assurance (QA) have not been feasible at this time. Analytics has played a huge role in contributing to our continued efforts of ensuring quality during the conduct of a clinical trial. Decisions driven through data, now more than ever, heavily contribute to the efficiency of QA activities. In this report, we share the approach we took to conduct QA activities for the COVACTA study (to treat Covid-19 pneumonia) by leveraging analytics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.